Trial Profile
Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Childhood Cerebral Adrenoleukodystrophy (CCALD)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs Sobetirome (Primary)
- Indications Adrenoleucodystrophy
- Focus Adverse reactions
- Sponsors NeuroVia
- 19 Jan 2020 This trial is discontinued in UK, according to European Clinical Trials Database record.
- 06 Mar 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 26 Jul 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 May 2018 to 1 Aug 2018.